Bempedoic Acid vs. Statins: Does Each LDL Drop Protect Equally?

Bempedoic acid appears to deliver about the same cardiovascular protection as a statin per unit of LDL cholesterol lowered. That is useful news for people who truly cannot tolerate statins. It does not mean the two treatments usually deliver the same total benefit.

A 2024 reanalysis of the CLEAR Outcomes trial estimated that each 1 mmol/L reduction in LDL-C with bempedoic acid corresponded to a hazard ratio of 0.75 for major vascular events (95% confidence interval, 0.63 to 0.90). The long-standing statin benchmark from the Cholesterol Treatment Trialists' Collaboration is a rate ratio of 0.78 per 1 mmol/L LDL-C reduction. Those estimates are statistically compatible, but bempedoic acid lowered LDL-C by only about 0.5 mmol/L in CLEAR. A moderate- or high-intensity statin often lowers it by roughly 1.0 to 2.0 mmol/L.

Efficiency and magnitude are different questions. Bempedoic acid may get similar cardiovascular benefit from each unit of LDL-C reduction, yet it usually has fewer units to work with.

What CLEAR Outcomes actually tested

CLEAR Outcomes randomized 13,970 people with hypercholesterolemia, high cardiovascular risk, and documented statin intolerance to bempedoic acid or placebo on top of standard care. The trial enrolled participants at 1,250 sites in 32 countries. This population matters: the trial tested an alternative for patients who could not tolerate the dominant lipid-lowering drug class, not a reason for statin-tolerant patients to abandon a treatment that works for them.

In the 2024 JACC analysis by Lincoff et al., a CTTC-equivalent major vascular event composite included coronary death, nonfatal myocardial infarction, fatal or nonfatal stroke, and coronary revascularization. Events occurred in 703 of 6,992 participants assigned bempedoic acid (10.1%) and 816 of 6,978 assigned placebo (11.7%). The hazard ratio was 0.85 (95% CI, 0.77 to 0.94), a statistically significant relative reduction.

The trial's primary four-component MACE endpoint included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and coronary revascularization. Bempedoic acid reduced that endpoint by 13% relative to placebo. A prespecified 2024 JAMA Cardiology analysis by Nicholls et al. also found fewer total cardiovascular events when it counted recurrent events as well as first events. That analysis supports the conclusion that the signal was not merely an artifact of a time-to-first-event calculation.

The per-mmol comparison is persuasive, not a head-to-head trial

The JACC investigators adjusted the observed outcome benefit to a standard 1 mmol/L LDL-C reduction. Their bempedoic acid estimate, 0.75, overlaps the CTTC statin reference estimate of 0.78. The bempedoic acid confidence interval includes the statin benchmark entirely, so the results are consistent with similar benefit per unit of LDL-C lowering.

This result fits the broader evidence that lowering LDL-C reduces atherosclerotic cardiovascular events across more than one mechanism. Statins inhibit HMG-CoA reductase; bempedoic acid inhibits ATP citrate lyase earlier in the cholesterol-synthesis pathway. Ezetimibe and PCSK9 inhibitors have also reduced major cardiovascular events in landmark randomized trials. As summarized in a clinical review by Ballantyne et al., the usual CTTC estimate is about a 22% reduction in major vascular events for every 1 mmol/L fall in LDL-C.

Still, "equivalent" reaches farther than the data do. The normalization was a post-hoc analysis, not a prespecified non-inferiority trial that randomized people directly to bempedoic acid or a statin. It compares CLEAR with an external statin benchmark drawn from other studies, populations, and treatment settings. A confidence interval that spans the statin estimate supports comparability; it does not prove identical effects.

A 2026 primary-prevention statin meta-analysis by Kalra et al. adds a further caution. It found heterogeneity in CTTC-derived per-mmol estimates across trial populations. CLEAR was predominantly primary prevention, while the broader statin evidence includes substantial secondary-prevention data. If the effect per mmol/L differs by baseline risk or prevention setting, one universal benchmark becomes less exact.

The practical limitation is the size of the LDL-C reduction

In CLEAR, bempedoic acid reduced LDL-C by 21% relative to placebo, or about 0.5 mmol/L from a baseline near 2.4 mmol/L. That predicted benefit is close to the trial's observed 13% relative MACE reduction: applying the 22% per-mmol statin benchmark to a 0.5 mmol/L reduction predicts roughly an 11% relative reduction.

The same arithmetic explains why a well-tolerated statin usually remains the stronger option. Moderate-intensity statins lower LDL-C by approximately 1.0 to 1.5 mmol/L; high-intensity regimens lower it by about 1.5 to 2.0 mmol/L. Bempedoic acid monotherapy therefore produces an LDL-C reduction roughly three to four times smaller than many high-intensity statin regimens. The trial showed a real patient-outcome benefit, but the absolute benefit for any individual still depends on baseline cardiovascular risk and on how much LDL-C falls.

If a patient needs more than about 0.5 mmol/L of LDL-C lowering to reach an agreed treatment target, bempedoic acid alone is unlikely to do the whole job. The fixed-dose bempedoic acid–ezetimibe combination can add LDL-C lowering, and PCSK9 inhibitors can produce larger reductions. A 2025 review of newer LDL-lowering therapies places bempedoic acid among the options for people who cannot reach targets with statins, rather than as a replacement for potent statin therapy in people who tolerate it.

Safety is a trade-off, not a free upgrade

Bempedoic acid has a reason to exist beyond LDL-C arithmetic. Statins can increase new-onset diabetes risk, and this concern helped motivate a prespecified CLEAR analysis. In a 2023 Lancet Diabetes & Endocrinology analysis by Ray et al., bempedoic acid showed a different diabetes-safety pattern from the established statin signal. The available published abstract information does not provide the per-group event rates needed to quantify that difference here, so it should not be turned into a precise risk claim.

Bempedoic acid also brings risks that statins do not share. Hyperuricemia and gout are clinically relevant concerns, and tendon rupture was an adverse event of interest in CLEAR. These risks may matter more than a theoretical diabetes advantage for someone with recurrent gout, elevated uric acid, or tendon disease. Conversely, muscle-symptom comparisons between CLEAR and statin trials would be misleading because CLEAR deliberately enrolled people with prior statin intolerance.

COVID-19 complicated trial follow-up and outcome ascertainment. A 2024 analysis of CLEAR's pandemic disruption describes the practical problems created by isolation restrictions. Missed outcomes could have biased effects toward no difference, but the size and direction of any resulting bias remain uncertain.

Who should consider it?

For people with genuine statin intolerance and elevated cardiovascular risk, bempedoic acid is an evidence-based option with randomized trial evidence for fewer cardiovascular events. The JACC reanalysis makes the mechanism-based case stronger: its event reduction per mmol/L of LDL-C lowering looks consistent with the statin benchmark.

For someone who tolerates a moderate- or high-intensity statin, the smaller LDL-C reduction is the decisive limitation. Switching simply to avoid side effects that have not occurred trades a larger expected LDL-C reduction for a smaller one, while introducing gout and tendon concerns.

Cost also belongs in the decision. A 2026 cost-effectiveness model based on CLEAR Outcomes evaluated bempedoic acid for high-risk, statin-intolerant patients and found potentially favorable value under its modeled assumptions. Models extend trial findings; they do not replace individual assessment of price, insurance coverage, baseline risk, and available alternatives.

Bempedoic acid is a credible substitute when statins are genuinely intolerable, not an equal-dose substitute for the LDL-C reduction a tolerated high-intensity statin can deliver.

One final reading rule applies to any drug-outcomes story: check the published funding and author disclosures alongside the results. The randomized evidence here is meaningful, but the per-unit comparison remains post-hoc and cross-study. Its most defensible conclusion is narrow: lower LDL-C with bempedoic acid, and cardiovascular risk falls in a way that is consistent with the established LDL-C framework. Whether that fall is enough depends on the patient's LDL-C goal and risk.